Hengrui Medicine (01276.HK) leads performance growth with sales of innovative drugs. In the first half of the year, the net profit attributable to the parent company was 4.45 billion yuan, a year-on-year increase of 29.7%.

Golden Finance News App news, Hengrui Medicine (01276.HK) announced its mid-term performance in 2025, with revenue of approximately RMB 15.761 billion, an increase of 15.9% compared to the same period last year; net profit attributable to the company's shareholders was RMB 4.45 billion, an increase of 29.7% compared to the same period last year; basic earnings per share were RMB 0.70.